ClinicalTrials.gg
RecruitingNCT07409753PAINOXYUpdated Nov 13, 2026

Effects Of Intravenous Oxytocin On Peripheral Sensory Afferents Using Microneurography

A Phase 2 interventional study of Intravenous Oxytocin and Intravenous Placebo in Acute Pain, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Wake Forest University Health Sciences · Phase 2, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2025, registered Jan 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if oxytocin reduces pain in a small area of skin after pulses of non-burning heat by changing how nerves in the heated area react to pressing a thin, bendable plastic bristle and a thick, non-bending plastic bristle in adult, healthy participants. The man questions it aims to answer are:

Does oxytocin increase the number of times a fiber which normally responds only to the thin bristle fires (sends a signal) after the heat pulses.

Does oxytocin raise the number of times a fiber which normally responds only to the thick bristle fires (sends a signal) after the heat pulses.

Researchers will compare oxytocin to a placebo (a look-alike substance that contains no drug) to see if oxytocin ABC works to change how nerves react to light touch and painful pressing in an area of sensitized skin.

Participants will:

Receive an intravenous injection of oxytocin or placebo on one occasion On the same day, a needle will be put near nerve fibers to record their firing before and after a few cycles of short heating of the skin.

Read the detailed description

This protocol will utilize a randomized, triple-masked study design to compare intravenous (IV) oxytocin to placebo on peripheral nerve response to acute pain sensitization in healthy volunteers. Equal numbers of adult men and women; ages 18-65 will be recruited. Participants, recruited from the regional community will report to the Linköping University Neurophysiologic Research Laboratory (Linköping, Sweden) for a 2-hour visit to complete eligibility screening, informed consent, pregnancy and drug use laboratory tests, and questionnaires regarding drug and alcohol use, and receive training in the tests to be used on the study day.

On a subsequent study day, participants will come initially to the Linköping University Medical Center where an IV catheter will be inserted and they will receive either IV oxytocin (20 IU) or an equal volume of placebo. Study drug will be randomized and administered in two 30-minute infusions separated by the minutes. Rapid rates of oxytocin infusion can cause acute adverse events in the first minutes of infusion. Although these adverse events rapidly resolve despite continuing the infusion, one event (facial flushing) could negate the blind of study personnel. For that reason, the first infusion will be given at 2 rates, a very slow rate for the first 5 minutes and a greater rate for the remaining 25 minutes. This has been demonstrated to reduce the incidence of facial flushing with oxytocin to a rate similar to placebo. Participants will be continuously monitored for vital signs and intermittently queried for any subjective sensations or adverse events during infusion.

After study drug infusion is complete, the IV catheter will be removed and the participant accompanied to the Linköping University Neurophysiologic Research Laboratory, adjacent to the Medical Center, where they will complete psychologic questionnaires and cognitive tests and undergo sensory testing of the skin on the arm of brushing using a computer controlled, robotic system. Then, a 200 micrometer tungsten electrode will be inserted in the radial or peroneal nerve under real-time ultrasound guidance and manipulated until a single nerve fiber and its area of skin innervation (receptive field) are identified. The nerve fiber will be categorized by its speed of conduction and firing pattern to a variety of non-noxious and noxious sensory stimuli to the receptive field. A temperature controlled thermode will be placed on the skin adjacent to and overlapping with the receptive field and acute inflammation induced by 10-second cycles of heating the probe to 50°C with 10 seconds at a non-noxious temperature (30°C) between each heat pulse for a total of 2 minutes. The response of the nerve fiber to noxious and non-noxious stimuli will be repeated.

The primary analysis will compare fiber firing in response to a fixed intensity punctate stimulus in the fiber's receptive field between oxytocin and placebo and will be performed separately on touch-sensitive fibers (fast conducting, low threshold mechanoreceptors (A-LTMRs)) and pain-sensitive fibers (fast conducting, low threshold mechanoreceptors (A-HTMRs)).

Based on numerous studies performed in rodents at Wake Forest University School of Medicine, the study team hypothesize that acute heat-induced inflammation will render A-LTMRs less responsive to a touch punctate stimulus and A-HTMRs more responsive to a noxious punctate stimulus and that both of these effects will be reduced by at least 50% in participants who receive IV oxytocin. If such results are obtained, the results will challenge the existing paradigm that reduction in pain threshold (allodynia) after sensitization from peripheral injury is driven by increased A-LTMR input and support further exploration for the mechanisms by which oxytocin returns changes in touch and pain fibers towards normal to treat pain.

02

Conditions studied

  • Acute Pain

Browse trials for

Keywords

  • healthy volunteers
  • pain control
  • oxytocin
03

In context

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

This study's planned enrollment of 60 is below the median of 86 across 905 interventional studies indexed under Acute Pain.

Browse Acute Pain studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.

Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In good health as determined by the Principal Investigator (PI) or co-investigators based on prior medical history, current psychiatric assessment, and clinical assessment of lab tests.
  • Female participants of including those \< 1 year , must be practicing highly effective methods of such as hormonal methods (e.g., combined oral, implantable, injectable, or transdermal contraceptives), double barrier methods (e.g., condoms, sponge, diaphragm, or vaginal ring plus spermicidal jellies or cream), or abstinence from heterosexual intercourse for a minimum of 1 full cycle before study drug administration.
  • Normal blood pressure (systolic 90-140 mmHg; diastolic 50-90 mmHg) resting heart rate 45-100 beats per minute) without medication.
  • Proficient in Swedish or English

Exclusion criteria

Exclusion Criteria:

  • , allergy, or a history of significant reaction to any ingredients of the active drug (Oxytocin Grindeks® 8.7 microgram/ml solution) or the placebo (Sodium Chloride , ATC code: V07AB).
  • Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the PI, would place the participant at increased risk (active gynecologic disease in which increased uterine tone would be detrimental e.g., uterine fibroids with ongoing bleeding), compromise the participant's compliance with study procedures, or compromise the quality of the data.
  • Women who are pregnant (positive result for urine pregnancy test at screening visit), women who are currently nursing or lactating, women that have been pregnant within 2 years.
  • (BMI) > 30
  • Participants with neuropathy, chronic pain, diabetes mellitus, or taking benzodiazepines or pain medications on a daily basis.
  • Participants with current or history of ventricular tachycardia, atrial fibrillation or prolonged .
  • Participants with past or current history of hyponatremia or at risk for hyponatremia; anyone taking thiazide diuretics, loop diuretics, combination diuretics, lithium, carbamazepine, enalapril, ramipril, celecoxib, temazepam, gliclazide, glimepiride, glibenclamide, glipizide, omeprazole, pantoprazole, desmopressin, antidepressants (SSRI's or MAOI), or the recreational drug ecstasy.
  • Participants with a known latex allergy.
  • Participants with substances use disorders or any other psychiatric disorder(s).
  • Participant with high risk of fainting episodes.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intravenous Oxytocin

    Oxytocin, 10 International Units (IU) will be administered by IV infusion over 30 minutes and, 30 minutes later, a second 10 IU will be administered over 30 min, for a total dose of 20 IU. The first infusion will be at a rate of 0.125 IU/min for the first 5 min, then at 0.375 IU/min for the remaining 25 min. The second 30-min infusion will be at a fixed rate of 0.333 IU/min.

    Drug: Intravenous Oxytocin

  • Placebo comparator
    Intravenous Placebo

    Saline will be administered as two 30-min IV infusions separated by 30-min, using the same volume of infusion solution and rates of administration as in the intravenous oxytocin intervention.

    Drug: Intravenous Placebo

Interventions

  • DrugOxytocinStudies of OxytocinOxytocin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous oxytocin, 20 IU will be administered via two 30-minute infusions separated by 30 minutes

    Also known as: Oxytocin-Grindeks

  • DrugIntravenous Placebo

    Intravenous placebo will be infused in the same volume and timing as the intravenous oxytocin intervention

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Number of nerve fiber discharges with von Frey filament application

    The number of nerve fiber discharges in response to a 5 second application of a 20 mN force von Frey filament and to a 1000 mN force von Frey filament to the area of skin responding to sensory stimulation. These are measured twice, once before and once after skin inflammation induced by heat pulses.

    Time frame: 2-8 hours after start of the first IV infusion

Secondary outcomes

  1. Verbal pain intensity score with von Frey filament application

    Verbal pain intensity score in response to a 5 second application of a 20 mN force von Frey filament and to a 1000 mN force von Frey filament to the area of skin responding to sensory stimulation. Pain scores are obtained twice, once before and once after skin inflammation induced by heat pulses. Pain intensity is rated on a 0-10 scale with 0 being no pain at all and 10 being the worst imaginable pain.

    Time frame: 2-8 hours after start of the first IV infusion

  2. Pattern of nerve fiber discharges with von Frey filament application

    The pattern of spikes in response to a 5 second application of 20 mN force von Frey filament and to a 1000 mN force von Frey filament to the area of skin responding to sensory stimulation. Pattern is categorized as one of 4 choices (rapidly adapting, slow adapting, continuous, or on-off) according to standard neurophysiological definitions. These will be measured twice, once before and once after heat-induced inflammation

    Time frame: 2-8 hours after start of the first IV infusion

  3. Number of nerve fiber burst discharges with tuning fork application

    The number of spike bursts in response to a 2 second application of a 128 Hz tuning fork to the receptive field. If there are any bursts to 128 Hz, then the test will be repeated with, separately, a 75 Hz tuning fork and a 512 Hz tuning fork to the area of skin responding to sensory stimulation. Spike bursts are defined as multiple spikes coinciding with each vibration of the tuning fork. These will be measured twice, once before and once after heat-induced inflammation

    Time frame: 2-8 hours after start of the first IV infusion

  4. Number of nerve fiber discharges with warming and cooling

    The number of discharges in response to slow warming to 50 degrees C and slow cooling to 0 degrees C by application of a Peltier-controlled thermode to the area of skin responding to sensory stimulation. Spike bursts are defined as multiple spikes coinciding with each vibration of the tuning fork. These will be measured twice, once before and once after heat-induced inflammation

    Time frame: 2-8 hours after start of the first IV infusion

  5. Number of nerve fiber discharges with soft brushing

    The number of discharges in response to brushing in the receptive field using a computer controlled robotic device at various pressures and speeds. Total discharges with each brush will be measured. The brushing tests will be performed twice, once before and once after heat-induced inflammation

    Time frame: 2-8 hours after start of the first IV infusion

  6. Number of nerve fiber discharges with von Frey filament application: stimulus response relationship

    The number of discharges in response to 5 sec application of von Frey filaments of 8 different forces from 4-3000 mN, presented in random order to the area of skin responding to sensory stimulation. Threshold will be determined as the lowest force resulting in any discharge. A stimulus response curve will be created using number of discharges to 5 second von Frey application at each of the 8 forces. This stimulus response is measured twice, once before and once after skin inflammation induced by heat pulses.

    Time frame: 2-8 hours after start of the first IV infusion

  7. Inflammation response to skin heating

    The area of erythema immediately after skin heating to 6 cycles of 50 degrees C for 10 sec over a total of 2 minutes will be calculated by measurement of height and width in mm, with values expressed in mm squared.

    Time frame: 2-8 hours after start of the first IV infusion

Other outcomes

  1. Exploratory outcome: Score on Digit Symbol Substitution Test (DSST)

    DSST is a measure of cognitive information processing speed. DSST is comprised of a paper sheet featuring a key at the top with numbers 1 to 9, each corresponding to a unique symbol. Below this key are five rows containing 25 randomly placed numbers without their associated symbols. Participants are given pencils to write the symbols, and are instructed to substitute as many numbers with their corresponding symbols as possible within a 90-second period, commencing with the leftmost symbol in the first row and proceeding from left to right. The test score is determined by accuracy: enumerating the quantity of correctly inserted symbols, with a range of 0 (no information processing) to 25 (highest information processing speed). It will be performed twice, once before and once after study drug administration in order to explore effects of oxytocin on information processing speed.

    Time frame: 1 hour before to 2 hr after start of the first IV infusion

  2. Exploratory outcome: Digit Span Test (DST)

    DST is a cognitive test of verbal working memory. Sequences are constructed of seven digits for forward recall and six digits for backward recall. Digits are not repeated within a sequence. A forward sequence is first read to the participant and they respond be repeating them in order. A backward sequence is first read to the participant and they respond by repeating them in reverse order, starting with the last digit. The maximum scored without making a mistake on the sequence is scored with a range 0 = no memory to 7 or 6 (maximum memory in forward and backward sequences, respectively) and the sum of these two (0-13) is the outcome score. DST will be performed twice, once before and once after study drug administration in order to explore effects of oxytocin on information processing speed.

    Time frame: 1 hour before to 2 hour after start of the first IV infusion

  3. Exploratory outcome: Rey Auditory Verbal Learning Test (RAVLT)

    RAVLT assesses verbal learning and memory. A list of 15 words (list A) is read 5o participants 5 times. After each reading (trial), participants are asked to recall as many words as they can (trials 1-5). Then a different list of 15 words is read to the participants, and they are asked to recall words from this list, (trial 6). Participants then are asked to recall words they had learned from List A without cues 5 min (short delayed recall; trial 7) and 30 min (long delayed recall; trial 8) after trial 6. Scores are calculated for (1) Total Immediate Recall (sum of words recalled in trials 1 to 5: range 0 = no recall, 15 = maximum recall); (2) Rate of Learning (trial 5 minus trial 1: range 0 = no learning, 15 = maximum learning); (3) Short Delayed Recall and Long Delayed Recall (at 5 and 30 min after trial 6, respectively) with range 0 - no long delayed recall to 15 - maximum delayed recall.

    Time frame: 30-60 minutes after completing the second IV infusion

  4. Exploratory outcome: Perceptual Aberrations Scale (PAS)

    PAS is a 35-item self-report questionnaire measuring body image and visual perception aberrations. It is scored on a True/False scale. Its total score ranges from 0 to 35 and it is calculated as the sum of the 'True' responses to all items, except four (i.e. items 6, 13, 24, 25) that are reverse-keyed. Scores range from 0 (no aberrations) to 35 (extreme aberrations).

    Time frame: 1 hour before to 2 hour after start of the first IV infusion

  5. Exploratory outcome: State-Trait Anxiety Scale (STAI)

    STAI is a 6-item self-report questionnaire measuring anxiety. It is scored on a 4 point Likert scale with positive items (calm, relaxed, content) reverse scored. Total score ranges from 20 (no anxiety) to 80 (severe anxiety)

    Time frame: 1 hour before to 2 hour after start of the first IV infusion

  6. Blood pressure

    Blood pressure will be measured non-invasively using an automated blood pressure cuff and values for systolic and diastolic pressure measured in mm Hg.

    Time frame: 0 to 6 hour after start of first IV infusion

  7. Heart rate

    Heart rate will be measured by the same device used to non-invasively measure blood pressure and will be expressed as beats per minute.

    Time frame: 0 to 6 hour after start of first IV infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Data will be anonymized and summarized in publications.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 19 months after the start.

Of 41 phase 2 interventional studies under Acute Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 19 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 13, 2026
StartActual
Oct 22, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 8, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
5 time frame changed
What changed in the outcomes
  • Time frameother outcomeExploratory outcome: Digit Span Test (DST)1 hour before to 2 hr after start of the first IV infusion → 1 hour before to 2 hour after start of the first IV infusion
  • Time frameother outcomeExploratory outcome: Perceptual Aberrations Scale (PAS)1 hour before to 2 hr after start of the first IV infusion → 1 hour before to 2 hour after start of the first IV infusion
  • Time frameother outcomeExploratory outcome: State-Trait Anxiety Scale (STAI)1 hour before to 2 hr after start of the first IV infusion → 1 hour before to 2 hour after start of the first IV infusion
  • Time frameother outcomeBlood pressure0 to 6 hr after start of first IV infusion → 0 to 6 hour after start of first IV infusion
  • Time frameother outcomeHeart rate0 to 6 hr after start of first IV infusion → 0 to 6 hour after start of first IV infusion
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Secondary outcomes 5 time frame changed
    What changed in the outcomes
    • Time frameother outcomeExploratory outcome: Digit Span Test (DST)1 hour before to 2 hr after start of the first IV infusion → 1 hour before to 2 hour after start of the first IV infusion
    • Time frameother outcomeExploratory outcome: Perceptual Aberrations Scale (PAS)1 hour before to 2 hr after start of the first IV infusion → 1 hour before to 2 hour after start of the first IV infusion
    • Time frameother outcomeExploratory outcome: State-Trait Anxiety Scale (STAI)1 hour before to 2 hr after start of the first IV infusion → 1 hour before to 2 hour after start of the first IV infusion
    • Time frameother outcomeBlood pressure0 to 6 hr after start of first IV infusion → 0 to 6 hour after start of first IV infusion
    • Time frameother outcomeHeart rate0 to 6 hr after start of first IV infusion → 0 to 6 hour after start of first IV infusion
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07409753
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Oct 22, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 8, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Hakan Olausson, MD, PhD
Contact
hakan.olausson@liu.se
+46 13286788
Saad Nagi, PhD
Contact
saad.nagi@liu.se
+46 13286823
James Eisenach, MD
study chair · Atrium Health Wake Forest University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxytocin

Start the discussion